by Summary:
Experts say it means there are "fewer obstacles for the immune system to neutralise the virus with antibodies". The world's biggest pharmaceutical company, Johnson & Johnson, told Sky News last month it was confident it had formulated a COVID-19 vaccine and wanted to make available on a not-for-profit basis in 2021. The firm hopes to begin human trials in September, which could mean mass production by early next year. The HIV comparison is significant, as the research was done using special equipment previously provided by a grant from the Bill and Melinda Gates Foundation through the Collaboration for AIDS Vaccine Discovery. Coronavirus: Vaccine hopes boosted as scientists find virus has 'low shielding'
Topics:
Mike Norman considers the following as important:
This could be interesting, too:
Experts say it means there are "fewer obstacles for the immune system to neutralise the virus with antibodies". The world's biggest pharmaceutical company, Johnson & Johnson, told Sky News last month it was confident it had formulated a COVID-19 vaccine and wanted to make available on a not-for-profit basis in 2021. The firm hopes to begin human trials in September, which could mean mass production by early next year. The HIV comparison is significant, as the research was done using special equipment previously provided by a grant from the Bill and Melinda Gates Foundation through the Collaboration for AIDS Vaccine Discovery. Coronavirus: Vaccine hopes boosted as scientists find virus has 'low shielding'
Topics:
Mike Norman considers the following as important:
This could be interesting, too:
New Economics Foundation writes Is the Labour government delivering on its promises?
John Quiggin writes Dispensing with the US-centric financial system
New Economics Foundation writes Whose growth is it anyway?
Matias Vernengo writes What is heterodox economics?
Experts say it means there are "fewer obstacles for the immune system to neutralise the virus with antibodies".
The world's biggest pharmaceutical company, Johnson & Johnson, told Sky News last month it was confident it had formulated a COVID-19 vaccine and wanted to make available on a not-for-profit basis in 2021.
The firm hopes to begin human trials in September, which could mean mass production by early next year.
The HIV comparison is significant, as the research was done using special equipment previously provided by a grant from the Bill and Melinda Gates Foundation through the Collaboration for AIDS Vaccine Discovery.